Announcements, press, and milestones.

About EpiBiologics

EpiBiologics was founded in 2021 and is headquartered in San Mateo, California. The company’s EpiTAC platform uses bispecific antibodies, with one arm binding a disease-causing target protein and the other binding a degradation receptor, to achieve targeted degradation of membrane and extracellular proteins. The company has also built an atlas of more than 270 degradation receptors.

Its lead candidate, EPI-326, is a tissue-selective, EGFR-degrading bispecific antibody that can degrade all oncogenic mutant forms of EGFR as well as wild-type EGFR. In April 2026, EPI-326 entered a global Phase 1 clinical trial in EGFR-driven non-small cell lung cancer and head and neck squamous cell carcinoma. The trial is currently in dose escalation, and clinical data could read out by mid-2027. The preclinical pipeline includes degrader–antibody-drug conjugates, a c-KIT programme and autoimmune programmes, among others.

In January 2026, the company completed a US$107 million Series B financing co-led by GV and Johnson & Johnson Innovation, with participation from Aulis Capital, Roche Venture Fund, Novartis Venture Fund and others.

The Aulis View

Unlike traditional protein degradation technologies, which focus on intracellular targets, EpiBiologics focuses on the emerging field of extracellular protein degradation. EPI-326 works regardless of mutation type and is tissue-selective, so it has the potential to address the resistance mutations and normal-tissue toxicity that limit existing EGFR therapies.

“Being recognised as a Fierce 15 company is a testament to the team’s relentless dedication to novel science and patient impact. At Aulis Capital, we couldn’t be prouder to partner with Ann Lee-Karlon and the visionary leadership team at EpiBiologics as they usher in the next wave of bispecific degrader therapeutics.”

— Nisa Leung, Founding Managing Partner, Aulis Capital

At Aulis Capital, we will continue to deepen our focus on life sciences innovation, partnering with outstanding entrepreneurs to bring breakthrough therapies to patients worldwide.

#EpiBiologics #Fierce15 #ProteinDegradation #EGFR #NSCLC #HNSCC #Biotech #VentureCapital

The continued evolution of Asia’s biopharma sector is reshaping discussions around innovation, competitiveness and global collaboration.

In the article, Franck explores what globalization could realistically look like for biopharma companies in Asia over the coming decade. The piece examines both the significant progress Asia has made in scientific innovation and the challenges of building globally scaled biopharma organizations.

It also highlights the growing role of cross-border partnerships, licensing transactions and innovation exchange in advancing drug development worldwide. Rather than viewing the future through a binary lens, it offers a nuanced perspective on how Asia-originated innovation may increasingly contribute to the global healthcare ecosystem.

As the industry continues to evolve, fostering collaboration across markets and innovation ecosystems will remain critical to accelerating the development of new therapies and improving patient outcomes worldwide.

The article can be accessed at the following link: https://www.biocentury.com/article/660965

#Biopharma #Biotechnology #LifeSciences #HealthcareInnovation #DrugDevelopment #DrugDiscovery #GlobalBiotech #HealthcareInvesting #Innovation #VentureCapital #LifeSciencesVC

More than 30 investors and business leaders from mainland China and Hong Kong discussed the healthcare capital lifecycle — from financing and clinical validation to regulatory pathways, commercialisation and international market access. Topics included the gap between China’s biotech pipeline and funding markets in the US and Europe, Hong Kong’s evolving role in biotech listings and exits, and the capital implications of AI-driven drug discovery.

We thank SCMP for organising the roundtable.

#Healthcare #Biotech #HongKong #CapitalMarkets #VentureCapital

One point anchored the discussion: innovation only matters to patients if it can actually reach them. Regulatory alignment, cross-border capital, and clinical data that travels across borders matter just as much as the science itself.

Hong Kong’s position was a focal point of the conversation — deep capital markets, proximity to the Greater Bay Area’s manufacturing and R&D base, and long-standing relationships with regulators across Asia-Pacific. That combination makes Hong Kong more than a financing hub: it is a credible bridge between Chinese innovation and the global patients who need it.

The panelists shared views on what it will actually take to build that trust: harmonized standards, more cross-border trial collaboration, and a shared commitment to patient outcomes.

We thank the panelists and BIOHK2026 for a candid conversation, and look forward to continuing it.

#BIOHK2026 #Biotech #HongKong #AsiaPacific #HealthcareInnovation #VentureCapital

The discussion covered how portfolio companies can navigate Asia’s capital ecosystem — from the nuances of markets across different hubs to what it takes to build credible, repeatable, and sustainable growth stories. Paul shared perspectives on the importance of global-mindedness, financial discipline, depth of value creation, strong corporate governance, and team readiness in creating meaningful outcomes for investors, regulators, patients and customers.

Moderator Anastasia Miros (CFGI) led the panel alongside Andrew Ng (VMS Group), Kenneth Sun (Royalty Pharma), and Jean-Baptiste Roy (Seveno Capital).

We thank MedTech World and our fellow panelists for a candid discussion on navigating the journey from Series A to IPO in Asia.

#MedTechWorld #MedTech #CapitalMarkets #VentureCapital #IPO #Asia #LifeSciences #Healthcare #Innovation

Mingyu noted that “AI is fundamentally a compressed ensemble of human knowledge” and shared how AI alone is not enough in a field as complex and data-constrained as life sciences.

The future lies in human-AI collaboration, combining scientific judgment with computational power. We believe AI will increasingly permeate the entire drug development process, transforming how therapies are discovered, translated, and delivered, while raising the quality and speed of innovation across the industry.

#AIDrugDiscovery #Biotech #ArtificialIntelligence #LifeSciences #DrugDevelopment #AIinHealthcare #PrecisionMedicine #HumanAICollaboration #BiotechInnovation #FutureOfMedicine

We are delighted to welcome Ethan Than to Aulis as Venture Partner. Ethan brings extensive experience as a biopharma operator and dealmaker, spanning drug development, strategic transactions, business development, and AI-enabled innovation. At Aulis, Ethan will work with our investment team, founders, and portfolio companies, bringing an operator’s and dealmaker’s perspective across investment evaluation, company building, and strategic growth.

The discussion covered three critical themes:

What defines a successful in-China strategy for health and life sciences MNCs in today’s rapidly shifting landscape.

How Chinese innovation is reshaping global R&D — and what companies need to do to keep pace or catch up.

Where Europe fits between the US and China, and its increasingly advantageous positioning in the global life sciences order.

These questions go to the heart of the opportunity — and the complexity — facing anyone operating at the intersection of global health and China’s innovation engine. We’re proud to have Franck’s perspective informing our work across the portfolio.

The full episode (video, audio and transcript) is available now: https://www.chinahealthpulse.com/p/the-china-decision-room-what-global

#Biotech #Biopharma #LifeSciences #GlobalHealth #VentureCapital #Innovation

Aulis Capital was represented at LEAP EAST Panel. Our founding Managing Partner spoke on the “From Lab to Unicorn: Building a Biotech Success Story in Asia” panel at LEAP East.

The conversation explored what it really takes to move breakthrough science out of the lab and into companies built to scale, from navigating regulatory pathways across Asian markets to building the right teams and securing capital at each stage of growth. Asia’s biotech ecosystem is maturing quickly, with strong momentum behind founders who can pair deep scientific expertise with sharp commercial execution.

We thank Michael Rinaman and Jia Zhuang for a thoughtful discussion, and to everyone who stopped by afterward to chat. Conversations like these are exactly why events like LEAP East matter, pushing the whole ecosystem forward.

Exciting times ahead for the next wave of Asian biotech innovation.

#LEAPEast #Biotech #LifeSciences #Asia #Innovation

Aulis was represented at BIO 2026, where Nisa joined a panel on cross-border biotech partnerships amid a shifting market — drawing a full room and overflow attendance. The discussion underscored that capital is recalibrating rather than retreating, with sustained appetite for scientifically differentiated assets. We thank co-panelists Lila Hope and Ken Song, and moderator June Lee, for the discussion. We look forward to Philadelphia in 2027.

#CrossBorderPartnerships #BiotechInvesting #GlobalHealth #Pharma #VentureCapital